谨慎开展、科学评价抗新生血管生成类药物治疗脉络膜新生血管  

Be cautious to treat choroidal neovascularization with anti-angiogenesis pharmacotherapy

作　　者：魏文斌[1] 莫静[1] 

机构地区：[1]首都医科大学附属北京同仁医院北京同仁眼科中心, 100730

出　　处：《中华眼科杂志》2008年第3期193-195,共3页Chinese Journal of Ophthalmology

摘　　要：随着全球老龄化的日益明显，脉络膜新生血管（CNV）特别是继发于年龄相关性黄斑变性的CNV日益成为一种严重的社会医学负担。近年来对于CNV病理机制的深入了解使得CNV的治疗得以进展，特别是靶向性的抗新生血管药物治疗获得了前所未有的成功。但是即便抗新生血管药物极具前景，我们仍然需要谨慎开展其临床应用，在临床中认真思考其安全性、有效性，摸索更合理的给药方案，探索联合治疗等，以寻找最理想的个性化治疗。Choroidal neovascularization （CNV） especially CNV secondary to age related macular degeneration is becoming an increasing socio-medical problem as the global population aging. Recently, with novel insights in the pathogenesis of the disease, anti-angiogenesis pharmacotherapy blated its way into ophthalmogical practice and significantly changed the management of CNV, since at the first time achieving improvement in visual function. However, facing such promising drugs, we still need to take caution with the safety, long-time efficacy ; to investigate more reasonable dosing schedule ; to study the combined treatment strategies and so on ,finally to find out the best individual clinical care for our patients. （Chin J Ophthalmol, 2008,44 ： 193-195）

关 键 词：脉络膜新生血管化 抗新生血管形成 药物治疗 

分 类 号：R686[医药卫生—骨科学]